Literature DB >> 22230871

Interaction between IL28B and PNPLA3 genotypes in the pathogenesis of steatosis in chronic hepatitis C non genotype-3 patients.

Luca Valenti, Alessio Aghemo, Albert Friedrich Stättermayer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22230871     DOI： 10.1016/j.jhep.2011.10.024

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  10 in total

1.  Understanding the role of PNPLA3 genetic variants in patients with chronic hepatitis C infection.

Authors:  Alessio Aghemo
Journal:  Dig Dis Sci       Date:  2012-06-27       Impact factor: 3.199

2.  The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infection.

Authors:  Paul J Clark; Alexander J Thompson; Qianqian Zhu; David M Vock; Mingfu Zhu; Keyur Patel; Stephen A Harrison; Susanna Naggie; Dongliang Ge; Hans L Tillmann; Thomas J Urban; Kevin Shianna; Jacques Fellay; Zachary Goodman; Stephanie Noviello; Lisa D Pedicone; Nezam Afdhal; Mark Sulkowski; Janice K Albrecht; David B Goldstein; John G McHutchison; Andrew J Muir
Journal:  Dig Dis Sci       Date:  2012-04-29       Impact factor: 3.199

Review 3.  PNPLA3 I148M polymorphism and progressive liver disease.

Authors:  Paola Dongiovanni; Benedetta Donati; Roberta Fares; Rosa Lombardi; Rosellina Margherita Mancina; Stefano Romeo; Luca Valenti
Journal:  World J Gastroenterol       Date:  2013-11-07       Impact factor: 5.742

4.  Interaction of IFNL3 with insulin resistance, steatosis and lipid metabolism in chronic hepatitis C virus infection.

Authors:  Mohammed Eslam; David R Booth; Jacob George; Golo Ahlenstiel
Journal:  World J Gastroenterol       Date:  2013-11-07       Impact factor: 5.742

5.  PNPLA3 polymorphism increases risk for and severity of chronic hepatitis C liver disease.

Authors:  Habeeb Salameh; Maen Masadeh; Muhannad Al Hanayneh; Vincent Petros; Matthew Maslonka; Arjun Nanda; Ashwani K Singal
Journal:  World J Hepatol       Date:  2016-12-18

6.  Impact of PNPLA3 and IFNL3 polymorphisms on hepatic steatosis in Asian patients with chronic hepatitis C.

Authors:  Chao-Min Huang; Kuo-Chin Chang; Chao-Hung Hung; King-Wah Chiu; Sheng-Nan Lu; Jing-Houng Wang; Chien-Hung Chen; Kwong-Ming Kee; Yuan-Hung Kuo; Ming-Chao Tsai; Po-Lin Tseng; Ming-Tsung Lin; Cheng-Kun Wu; Tsung-Hui Hu; Chung-Lung Cho; Yi-Hao Yen
Journal:  PLoS One       Date:  2017-08-10       Impact factor: 3.240

7.  Duplex High-Resolution Melting Assay for the Simultaneous Genotyping of IL28B rs12979860 and PNPLA3 rs738409 Polymorphisms in Chronic Hepatitis C Patients.

Authors:  Elena L Enache; Anca Sin; Ligia Bancu; Christophe Ramière; Olivier Diaz; Patrice André; Liviu S Enache
Journal:  Int J Mol Sci       Date:  2015-09-14       Impact factor: 5.923

8.  Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment.

Authors:  Paola Dongiovanni; Quentin M Anstee; Luca Valenti
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

9.  Interaction between PNPLA3 I148M variant and age at infection in determining fibrosis progression in chronic hepatitis C.

Authors:  Stella De Nicola; Paola Dongiovanni; Alessio Aghemo; Cristina Cheroni; Roberta D'Ambrosio; Michele Pedrazzini; Francesco Marabita; Lorena Donnici; Marco Maggioni; Silvia Fargion; Massimo Colombo; Raffaele De Francesco; Luca Valenti
Journal:  PLoS One       Date:  2014-08-29       Impact factor: 3.240

Review 10.  PNPLA3 rs738409 Polymorphism Associated with Hepatic Steatosis and Advanced Fibrosis in Patients with Chronic Hepatitis C Virus: A Meta-Analysis.

Authors:  Jia-Hao Fan; Ming-Que Xiang; Qing-Ling Li; Hong-Tao Shi; Jin-Jun Guo
Journal:  Gut Liver       Date:  2016-05-23       Impact factor: 4.519
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.